Activity of selected metalloproteinases in neurodegenerative diseases of the central nervous system as exemplified by dementia and schizophrenia

被引:2
|
作者
Tylec, Aneta [1 ]
Skalecki, Maciej [2 ]
Kocot, Joanna [3 ]
Kurzepa, Jacek [3 ]
机构
[1] Uniw Med Lublinie, Klin Psychiat & Rehabil Psychiat 2, Lublin, Poland
[2] Samodzielny Publ Psychiat Zaklad Opiek Leczniczy, Lublin, Poland
[3] Uniw Med Lublinie, Katedra & Zaklad Chem Med, Lublin, Poland
关键词
extracellular matrix metalloproteinase; tissue metalloproteinase inhibitor; neurodegenerative disease; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; MATRIX-METALLOPROTEINASE-9; GENE; BRAIN; POLYMORPHISM; INHIBITORS; PROTEIN; GENDER; AGE;
D O I
10.12740/PP/126662
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Aim. The aim of the study was to determine and analyze the correlation between the concentrations of selected metalloproteinases and their inhibitors (TIMP-1 and TIMP-2) in patients with dementia and schizophrenia. Method. The concentration of two collagenases and metalloendopeptidase was determined in the study. The study included 29 patients with late onset dementia, 25 patients with paranoid schizophrenia and 25 healthy controls who were age-matched with the study groups. Symptoms of dementia were evaluated using the Short Mental State Assessment Scale, whereas the symptoms of schizophrenia were assessed using the Positive and Negative Assessment Scale. Blood samples were collected from the participants and the concentrations of MMP-1, MMP7, MMP-13, TIMP-1, and TIMP-2 in the blood serum were evaluated using ELISA method. Results. A two-fold increase in the concentration of MMP-1 and a slight increase in MMP-13 was observed in dementia patients compared to other groups, as well as a lower level of MMP-7 and TIMP-1 and a higher level of TIMP-2 compared to the control group. Patients with schizophrenia showed lower MMP-7 and higher TIMP-2 serum level compared to the controls. No differences in the concentration of MMP-1, MMP-13 and TIMP-1 levels were noticed. In people with late onset dementia an increase in collagenolytic activity was demonstrated. Conclusions. Increase in collagenolytic activity may indicate an increased remodeling within the central nervous system in late onset dementia. The difference in the fluctuation of the concentrations of the studied enzymes and their inhibitors in dementia and schizophrenia indicates their different involvement in the pathogenesis of these disorders. Slowa klucze: metaloproteinaza macierzy zewnatrzkomorkowej, tkankowy inhibitor meta-loproteinazy, choroba neurodegeneracyjna
引用
收藏
页码:1221 / 1233
页数:13
相关论文
共 50 条
  • [41] Restless legs syndrome in Parkinson's disease and other neurodegenerative diseases of the central nervous system
    Iranzo, Alex
    Comella, Cynthia L.
    Santamaria, Joan
    Oertel, Wolfgang
    MOVEMENT DISORDERS, 2007, 22 : S424 - S430
  • [42] Changes in iron load in specific brain areas lead to neurodegenerative diseases of the central nervous system
    Wang, Xinghao
    Zhu, Zaimin
    Sun, Jing
    Jia, Li
    Cai, Linkun
    Chen, Qian
    Yang, Wenbo
    Wang, Yiling
    Zhang, Yufan
    Guo, Sihui
    Liu, Wenjuan
    Yang, Zhenghan
    Zhao, Pengfei
    Wang, Zhenchang
    Lv, Han
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2024, 129
  • [43] Meningeal lymphatic vessel crosstalk with central nervous system immune cells in aging and neurodegenerative diseases
    Minghuang Gao
    Xinyue Wang
    Shijie Su
    Weicheng Feng
    Yaona Lai
    Kongli Huang
    Dandan Cao
    Qi Wang
    Neural Regeneration Research, 2025, 20 (03) : 763 - 778
  • [44] Chaperone-Mediated Autophagy in Neurodegenerative Diseases and Acute Neurological Insults in the Central Nervous System
    Kanno, Haruo
    Handa, Kyoichi
    Murakami, Taishi
    Aizawa, Toshimi
    Ozawa, Hiroshi
    CELLS, 2022, 11 (07)
  • [45] Coenzyme Q(10) in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases
    Beal, MF
    Matthews, RT
    MOLECULAR ASPECTS OF MEDICINE, 1997, 18 : S169 - S179
  • [46] A Review of Stem Cell Therapy for Acquired Brain Injuries and Neurodegenerative Central Nervous System Diseases
    Watanabe, Thomas K.
    PM&R, 2018, 10 (09) : S151 - S156
  • [47] Retinal OCT biomarkers and neurodegenerative diseases of the central nervous system beyond Alzheimer's disease
    Hopf, Susanne
    Tuescher, Oliver
    Schuster, Alexander K.
    OPHTHALMOLOGIE, 2024, 121 (02): : 93 - 104
  • [48] Meningeal lymphatic vessel crosstalk with central nervous system immune cells in aging and neurodegenerative diseases
    Gao, Minghuang
    Wang, Xinyue
    Su, Shijie
    Feng, Weicheng
    Lai, Yaona
    Huang, Kongli
    Cao, Dandan
    Wang, Qi
    NEURAL REGENERATION RESEARCH, 2025, 20 (03) : 763 - 778
  • [49] Gene transfer into the central and peripheral nervous system: Applications for the treatment of neurodegenerative diseases and peripheral neuropathies
    Pradat, PF
    Mallet, J
    BIOTECHNOLOGY & GENETIC ENGINEERING REVIEWS, VOL 20, 2003, 20 : 49 - 76
  • [50] Metallothioneins and the Central Nervous System: From a Deregulation in Neurodegenerative Diseases to the Development of New Therapeutic Approaches
    Bolognin, Silvia
    Cozzi, Bruno
    Zambenedetti, Pamela
    Zatta, Paolo
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 41 (01) : 29 - 42